NeoGenome, founded in 2020, is spearheading the development of GMO-based solutions that are transforming the chemical manufacturing industry. The company's flagship product is lactic acid, produced using cutting-edge technology, which not only offers a 40% reduction in production costs compared to traditional methods but also brings significant environmental benefits. NeoGenome's commitment to sustainability is reflected in its Biotechnology focus, aiming to offer cost-effective and environmentally friendly chemicals. Although specific details regarding the headquarters, last investment, and investors are currently unavailable, NeoGenome's innovative approach positions it as a promising venture for venture capitalists seeking to support groundbreaking advancements in biotechnology. With its potential to disrupt the industry and drive impactful change, NeoGenome presents an intriguing opportunity for potential investors in the biotechnology sector.
There is no investment information
No recent news or press coverage available for NeoGenome.